Treatment with obinutuzumab along with chemotherapy resulted in longer progression-free survival than rituximab and chemotherapy in patients with previously untreated advanced-stage follicular lymphoma, according to a large randomized trial.
A new study found significant gaps in the monitoring of responses to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Patients are more likely to be monitored in Europe, at academic centers, and if they are younger than 65.
Maintenance therapy with rituximab following autologous stem cell transplantation prolonged progression-free, event-free, and overall survival compared with observation in patients with mantle cell lymphoma, according to a new study.
Non-Hodgkin lymphoma patients who have preexisting cardiovascular risk factors are at an increased risk of heart failure and are often prescribed anthracyclines less frequently, according to a large population-based study.